A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors - Trial NCT06235541
Access comprehensive clinical trial information for NCT06235541 through Pure Global AI's free database. This Phase 1 trial is sponsored by Genome & Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Genome & Company
Timeline & Enrollment
Phase 1
Feb 01, 2024
May 01, 2027
Primary Outcome
To determine the MTD and RP2D,Incidence of Adverse Events,Incidence of Laboratory abnormalities
Summary
This is a first in human phase I , open label study to evaluate the safety and tolerability
 of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1
 cycle = 2 weeks) in patients with advanced solid tumors, for who no standard therapy exists,
 or standard therapy has failed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06235541
Non-Device Trial